1️⃣ Lilly bought a preclinical delivery wedge Lilly acquired Engage Bio for up to $202 million in cash, adding Tethosome, a non-viral DNA delivery platform built around potency, tolerability and redosing.
💡 Why it matters Genetic medicine value is moving back to delivery. Lilly is buying optionality before human data, because the platform slot may matter more than the first asset.
☕ Coffee talk How many seed-stage delivery companies now look strategic just because Lilly keeps paying early?
2️⃣ Parabilis tests the IPO window with Regeneron beside it Parabilis filed for a Nasdaq IPO after a Regeneron collaboration with $50 million upfront and a planned $75 million equity buy, with proceeds earmarked for Phase 3 zolucatetide in desmoid tumors.
💡 Why it matters This is the cleaner version of biotech reopening: pharma validation, a late-stage lead and a platform story. Public buyers still have to price beta-catenin risk.
☕ Coffee talk Does the IPO market want platform ambition, or just Mathai Mammen plus a Regeneron cheque?
3️⃣ Incyte pays for proprietary-data AI Incyte expanded its Genesis Molecular AI pact with $120 million upfront consideration, including $80 million cash and $40 million equity, adding at least five discovery targets.
💡 Why it matters The signal is not “AI in discovery”. It is a mid-cap biotech paying for an owned data loop tied to exclusive programs and per-program milestones.
☕ Coffee talk How many AI discovery companies can still sell demos once pharma asks for a real design-make-test loop?